Todos Medical partner NLC Pharma assigns IP for Tollovir, Tollovid, and TolloTest to 3CL Pharma

Todos Medical Ltd. (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive’s Stephen Gunnion that the company has completed a key milestone in its joint venture with NLC Pharma, with the transfer of its Tollovir, Tollovid, and TolloTest intellectual property to 3CL Pharma Ltd.

Commissiong said 3CL Pharma will now prepare to launch a crowdfunding campaign to fund an Emergency Use Authorization (EUA) submission to the US Federal Drug Administration (FDA) for Tollovir in the treatment of hospitalized, severe to critical COVID-19 patients, the clinical development of Tollovir, Tollovid and TolloTest in Long COVID, as well as a national marketing campaign for Tollovid to support US sales.

He also highlighted news that Tollovid has featured in the latest issue of Wellness Magazine.

#ProactiveInvestors #TodosMedical #Tollovid #Tollovir #TolloTest #3CLPharma #OTCQB #CrowdFunding

You might like

© 2022 The Latest StockMarket News and Interviews